Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 1, 2025
Distillery Therapeutics
Inhibiting interactions between FAM171A2 and alpha-synuclein for Parkinson’s disease
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Sep 1, 2023
Finance
Sept. 1 Quick Takes: mRNA play Innovac raises $18M series pre-A round
Plus: Roche’s Alecensa meets in ALK-positive NSCLC and updates from Carisma and FindCure
BioCentury | Aug 25, 2023
Finance
Aug. 24 Quick Takes: Ferring banks $300M up front in Royalty Pharma deal
Plus: Aprinoia, SPAC terminate merger agreement and Exelixis’ cabozantinib shows PFS benefit in NETs and updates on the IRA, RSV and more
BioCentury | Feb 7, 2023
Management Tracks
Astellas shuffles top management amid push to reshape strategically
As pharma implements growth plan to look beyond Xtandi, rising CEO Okamura figures to execute on launches, develop in newer modalities
BioCentury | Nov 4, 2022
Deals
Nov. 4 Quick Takes: Bayer returns rights to Ionis’ antithrombotic
Plus Vicore gains on IPF data and updates from Acrivon, BioAtla, Novadip and more
BioCentury | Apr 20, 2022
Data Byte
The Phase III pipeline for ovarian cancer
Companies are testing 15 therapies across four mechanisms; five trials to report data this year
BioCentury | Jan 8, 2022
Management Tracks
Totus recruits Singer as first CFO
Plus updates from Pharmaron, Adverum, Azenta, InterVenn and more
BioCentury | Nov 19, 2021
Deals
Momentum for TIGIT, adenosine with Gilead’s grab of Arcus options
While disclosed data remain limited, Gilead highlights potential for combos
BioCentury | Aug 6, 2021
Management Tracks
Zymergen expands its C-suite
Plus: Telix, MEI, Kallyope, BerGenBio and iOnctura
Items per page:
1 - 10 of 160